Dendritic Cells Transduced with an Adenoviral Vector Encoding a Model Tumor-Associated Antigen for Tumor Vaccination

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Human Gene Therapy

• Publication date

  1997-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/hum.1997.8.11-1355PMID 9295130
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recombinant adeno-associated virus for muscle directed gene therapy

  1997cited by this paper
• Immunophenotypic characterization of Epstein-Barr virus-associated gastric carcinoma: massive infiltration by proliferating CD8+ T-lymphocytes.

  1996cited by this paper
• Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

  1996cited by this paper
• Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.

  1996cited by this paper
• Induction of antitumor immunity using bone marrow-generated dendritic cells.

  1996cited by this paper
• Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.

  1996cited by this paper
• In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector.

  1996cited by this paper
• The functional half‐life of H‐2Kd‐restricted T cell epitopes on living cells

  1996cited by this paper
• Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

  1996cited by this paper
• Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice.

  1996cited by this paper
• New insights into the mobilization and phagocytic activity of dendritic cells

  1996cited by this paper
• Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

  1996cited by this paper
• Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo.

  1995cited by this paper
• Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

  1995cited by this paper
• Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses

  1995cited by this paper
• Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model.

  1995cited by this paper
• Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?

  1995cited by this paper
• Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor.

  1995cited by this paper
• The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants.

  1995cited by this paper
• The use of adenoviral vectors for gene therapy and gene transfer in vivo.

  1995cited by this paper
• T cell priming versus T cell tolerance induced by synthetic peptides

  1995cited by this paper
• Genes coding for tumor rejection antigens: perspectives for specific immunotherapy.

  1994cited by this paper
• Tumour antigens. A new look for the 1990s.

  1994cited by this paper
• Cancer antigens: immune recognition of self and altered self

  1994cited by this paper
• A new look for the 1990s

  1994cited by this paper
• Use of recombinant adenovirus for metabolic engineering of mammalian cells.

  1994cited by this paper
• MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses.

  1994cited by this paper
• Adenovirus-mediated cytokine gene transfer at tissue sites. Overexpression of IL-6 induces lymphocytic hyperplasia in the lung.

  1994cited by this paper
• Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo

  1994cited by this paper
• An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3.

  1994cited by this paper
• Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells.

  1993cited by this paper
• Monitoring foreign gene expression by a human adenovirus-based vector using the firefly luciferase gene as a reporter.

  1993cited by this paper
• Dendritic cells: antigen presentation, accessory function and clinical relevance.

  1993cited by this paper
• Evidence that the middle T antigen of polyomavirus interacts with the membrane skeleton

  1993cited by this paper
• Packaging capacity and stability of human adenovirus type 5 vectors

  1993cited by this paper
• MHC antigens and cancer: implications for T-cell surveillance.

  1992cited by this paper
• Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease

  1992cited by this paper
• Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.

  1992cited by this paper
• Adenovirus-based expression vectors and recombinant vaccines.

  1992cited by this paper
• Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

  1992cited by this paper
• Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection

  1990cited by this paper
• Suppression of MHC class I RNA in highly oncogenic cells occurs at the level of transcription initiation.

  1989cited by this paper
• An antigen-independent contact mechanism as an early step in T cell- proliferative responses to dendritic cells

  1989cited by this paper
• Migration patterns of dendritic cells in the mouse. Homing to T cell- dependent areas of spleen, and binding within marginal zone

  1988cited by this paper
• Migration patterns of dendritic cells in the mouse. Traffic from the blood, and T cell-dependent and -independent entry to lymphoid tissues

  1988cited by this paper
• Overproduction of polyomavirus middle T antigen in mammalian cells through the use of an adenovirus vector

  1987cited by this paper
• Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer

  1985cited by this paper

• Dendritic Cell Vaccine Harboring Inactivated Mycobacteria Induces Immune Protection Against Tuberculosis in Murine Models and is Well Tolerated in Humans

  2024cites this paper
• Trial watch: anticancer vaccination with dendritic cells

  2024cites this paper
• Persistent Antigen Harbored by Alveolar Macrophages Enhances the Maintenance of Lung-Resident Memory CD8+ T Cells

  2022cites this paper
• Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

  2022cites this paper
• Trial watch: dendritic cell vaccination for cancer immunotherapy

  2019cites this paper
• Trial watch: Dendritic cell-based anticancer immunotherapy

  2017cites this paper
• Tumor Microenvironment

  2017cites this paper
• Cancer vaccines

  2015cites this paper
• Dendritic cell immunotherapy for brain tumors

  2015cites this paper
• Trial watch: Dendritic cell-based anticancer therapy

  2014cites this paper
• TARGETING THE TUMOUR ASSOCIATED ANTIGENS PLAC1 AND GP100 WITH ONCOLYTIC CANCER VACCINES

  2013cites this paper
• Antigen Targeting to Dendritic Cells for Cancer Immunotherapy

  2013cites this paper
• Trial watch

  2013cites this paper
• Vaccine Efficacy and Maturation of Murine Dendritic Cells Fiber-Mutant Adenovirus Vectors Can Potentiate Antitumor Efficient Antigen Gene Transduction Using Arg-Gly-Asp

  2013cites this paper
• Trial watch

  2012cites this paper
• Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model

  2011cites this paper
• INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect

  2010cites this paper
• Gene-Modified Dendritic Cells for Use in Tumor Vaccines

  2009influential citation
• Novel insights into the in vivo biology of Interleukin-10.

  2009cites this paper
• Enhanced Antitumor Immunity Elicited by Dendritic Cell Vaccines Is a Result of Their Ability to Engage Both CTL and IFNγ-producing NK Cells.

  2008cites this paper
• Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells.

  2008cites this paper
• HLA-Ligandom- und Expressions-Analyse von Tumor- und Autophagie-assoziierten Antigenen in soliden Tumoren und Zelllinien

  2008cites this paper
• Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in Non-Small Cell Lung Cancer

  2008cites this paper
• Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.

  2006cites this paper
• An adenoviral vector for probing promoter activity in primary immune cells.

  2006cites this paper
• Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth.

  2006cites this paper
• The CD8+ T Cell Population Elicited by Recombinant Adenovirus Displays a Novel Partially Exhausted Phenotype Associated with Prolonged Antigen Presentation That Nonetheless Provides Long-Term Immunity1

  2006cites this paper
• Development of cell-based tuberculosis vaccines: genetically modified dendritic cell vaccine is a much more potent activator of CD4 and CD8 T cells than peptide- or protein-loaded counterparts.

  2006cites this paper
• Preclinical Safety and Biodistribution of Adenovirus-Based Cancer Vaccines After Intradermal Delivery

  2006cites this paper
• Adenoviral‐encoded antigens are presented efficiently by a subset of dendritic cells expressing high levels of αvβ3 integrins

  2006cites this paper
• Different Approaches to Dendritic Cell-Based Cancer Immunotherapy

  2006cites this paper
• Chapter 21 – Vaccination to Treat Noninfectious Diseases: Surveying the Opportunities

  2006cites this paper
• Highly Efficient and Consistent Gene Transfer into Dendritic Cells Utilizing a Combination of Ultraviolet-irradiated Adenovirus and Poly ( L-Lysine ) Conjugates 1

  2006cites this paper
• Crystal Cells and Suppresses Tumor Growth to Murine Tumors Induces the Accumulation of Dendritic Derived Factor-1 − Adenoviral Gene Transfer of Stromal Cell

  2006cites this paper
• Patient‐derived dendritic cells transduced with an a‐fetoprotein‐encoding adenovirus and co‐cultured with autologous cytokine‐induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells

  2006cites this paper
• Dendritic Cell-Based Genetic Immunotherapy for Ovarian Cancer

  2006cites this paper
• Vaccination therapy in malignant disease.

  2006cites this paper
• Induction of Antigen-Specific Immune Responses in Vivo After Vaccination with Dendritic Cells Transduced with Adenoviral Vectors Encoding Hepatitis C Virus NS3

  2006cites this paper
• Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors.

  2006cites this paper
• Induction of Tc1 response and enhanced cytotoxic T lymphocyte activity in mice by dendritic cells transduced with adenovirus expressing HBsAg.

  2006cites this paper
• Adenoviral-encoded antigens are presented efficiently by a subset of dendritic cells expressing high levels of alpha(v)beta3 integrins.

  2006cites this paper
• Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells

  2005cites this paper
• Long-Term Immunity with Prolonged Antigen Presentation That Partially Exhausted Phenotype Associated Recombinant Adenovirus Displays a Novel T Cell Population Elicited by + The CD 8

  2005cites this paper
• The CD8 T Cell Population Elicited by Recombinant Adenovirus Displays a Novel Partially Exhausted Phenotype Associated with Prolonged Antigen Presentation That Nonetheless Provides Long-Term Immunity

  2005cites this paper
• Clinical trials with tumor antigen genetically modified dendritic cells.

  2005cites this paper
• Activation of antigen-presenting cells by DNA delivery vectors

  2005cites this paper
• Adenovirus Transduction and Culture Conditions Affect the Immunogenicity of Murine Dendritic Cells

  2005cites this paper
• Gene transfer to dendritic cells induced a protective immunity against melanoma.

  2005cites this paper
• Adenovirus-mediated transgene-engineered dendritic cell vaccine of cancer.

  2005cites this paper
• In vitro dendritic cell infection by pseudotyped adenoviral vectors does not correlate with their in vivo immunogenicity.

  2005cites this paper
• Genetically modified dendritic cells for cancer immunotherapy.

  2005cites this paper
• Antitumor activity of a fusion of esophageal carcinoma cells with dendritic cells derived from cord blood.

  2005cites this paper
• Transduction of dendritic cells with recombinant adenovirus encoding HCA661 activates autologous cytotoxic T lymphocytes to target hepatoma cells

  2004cites this paper
• Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

  2004cites this paper
• Cellular immunotherapy for cancer: current concepts and clinical perspectives Monitoring immune responses and clinical trials: part II.

  2004cites this paper
• Vaccination-Induced Autoimmune Vitiligo Is a Consequence of Secondary Trauma to the Skin

  2004cites this paper
• Early Adenoviral Gene Expression Mediates Immunosuppression by Transduced Dendritic Cell (DC): Implications for Immunotherapy Using Genetically Modified DC1

  2004cites this paper
• Vaccination with helper-dependent adenovirus enhances the generation of transgene-specific CTL

  2004cites this paper
• CTL-Dependent and -Independent Antitumor Immunity Is Determined by the Tumor Not the Vaccine1

  2004cites this paper
• Utility of Adenovirus-Based Vectors for Multiple Cancer Vaccine Approaches

  2004cites this paper
• Cellular immunotherapy for cancer: current concepts and clinical perspectives scientific basis and approaches for therapeutic cancer vaccines. Part I.

  2004cites this paper
• Utilization of adenovirus vectors for multiple gene transfer applications.

  2004cites this paper
• Generierung und Charakterisierung einer kontinuierlich proliferierenden dendritischen Zelllinie der NOD-Maus

  2003cites this paper
• In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses.

  2003cites this paper
• Murine Cytomegalovirus Abortively Infects Human Dendritic Cells, Leading to Expression and Presentation of Virally Vectored Genes

  2003cites this paper
• Full-length dominant-negative survivin for cancer immunotherapy.

  2003cites this paper
• Adenoviral Transgene Ubiquitination Enhances Mouse Immunization and Class I Presentation by Human Dendritic Cells

  2003cites this paper
• Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy

  2003cites this paper
• Cryopreservation of immature monocyte-derived dendritic cells results in enhanced cell maturation but reduced endocytic activity and efficiency of adenoviral transduction.

  2003cites this paper
• Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines

  2003cites this paper
• Protection Against Experimental Autoimmune Encephalomyelitis Generated by a Recombinant Adenovirus Vector Expressing the Vβ8.2 TCR Is Disrupted by Coadministration with Vectors Expressing Either IL-4 or -101

  2003cites this paper
• Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies.

  2003cites this paper
• Immunization of Patients with Malignant Melanoma with Autologous CD34+ Cell-Derived Dendritic Cells Transduced Ex Vivo with a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial

  2003cites this paper
• Recent patents on experimental therapy for hepatitis C virus infection (1999 – 2002)

  2003cites this paper
• Effect of adenovirus gene transfer vectors on the immunologic functions of mouse dendritic cells.

  2002cites this paper
• DNA‐based immunotherapy: potential for treatment of chronic viral hepatitis?

  2002cites this paper
• Infection of mouse bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design.

  2002cites this paper
• The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen

  2002cites this paper
• Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?

  2002cites this paper
• Current issues in dendritic cell cancer immunotherapy.

  2002cites this paper
• Charakterisierung der Bedeutung einer Zellpermeabilität vermittelnden Region für den Lebenszyklus des Hepatitis B-Virus und Etablierung von zellpermeablen Nukleokapsiden für den Protein und Gentransfer

  2002cites this paper
• Enhanced Efficiency by Centrifugal Manipulation of Adenovirus-Mediated Interleukin 12 Gene Transduction into Human Monocyte-Derived Dendritic Cells

  2001cites this paper
• Can dendritic cells be exploited for therapeutic intervention in atherosclerosis?

  2001cites this paper
• Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors.

  2001cites this paper
• Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.

  2001cites this paper
• Genetically modified dendritic cells in cancer therapy: implications for transfusion medicine.

  2001cites this paper
• Adenoviral-vector-mediated gene transfer to dendritic cells.

  2001cites this paper
• STRATEGIES TO PROMOTE TOLERANCE INDUCTION USING DENDRITIC CELLS

  2001cites this paper
• CHAPTER 43 – Genetic engineering of dendritic cells

  2001cites this paper
• Maturation of dendritic cells infected by recombinant adenovirus can be delayed without impact on transgene expression

  2001cites this paper
• CHAPTER 42 – Dendritic cell tolerogenicity and prospects for dendritic cell-based therapy of allograft rejection and autoimmune disease

  2001cites this paper
• Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12

  2001cites this paper
• Adenovirally Modified Dendritic Cells for Immunotherapy: From Basic Development to Clinical Application

  2001cites this paper
• Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells.

  2001cites this paper
• Novel centrifugal method for simple and highly efficient adenovirus-mediated green fluorescence protein gene transduction into human monocyte-derived dendritic cells.

  2001cites this paper
• [Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors].

  2001cites this paper
• Dendritic Cells Transduced with HSV-1 Amplicons Expressing Prostate-Specific Antigen Generate Antitumor Immunity in Mice

  2001cites this paper
• Lentiviral Vector-Mediated Tyrosinase-Related Protein 2 Gene Transfer to Dendritic Cells for the Therapy of Melanoma

  2001cites this paper
• Specific Immunotherapy of Cancer in Elderly Patients

  2001cites this paper
• Animal Cell Technology: From Target to Market

  2001cites this paper